### SCIENTIFIC PROGRAM (as of June 05, 2017)

**Tuesday, June 13, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 17:30</td>
<td>Auditorium (Lugano University)</td>
<td><strong>CLOSED WORKSHOP - DESIGN OF CLINICAL TRIALS: BIOLOGICAL AND CLINICAL ENDPOINTS IN THE DESIGN OF FUTURE CLINICAL TRIALS</strong>&lt;br&gt;Co-chairs: A. Younes, New York, NY (USA) and E. Zucca, Bellinzona (Switzerland)&lt;br&gt;Organized in co-operation with American Association for Cancer Research – AACR and European School of Oncology – ESO&lt;br&gt;<em>by invitation only</em></td>
</tr>
<tr>
<td>15:00 – 17:30</td>
<td>Aula Magna (Lugano University)</td>
<td><strong>WORKSHOP - NOVEL ISSUES IN THE COMBINED MODALITY TREATMENT OF LYMPHOMAS</strong>&lt;br&gt;Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark)&lt;br&gt;Organized by International Lymphoma Radiation Oncology Group - ILROG&lt;br&gt;<em>open to all 14-ICML attendees</em></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td><strong>PART 1: IMMUNOMODULATORY TREATMENT IN THE COMBINED MODALITY SETTING</strong>&lt;br&gt;<strong>IMMUNOMODULATORY TREATMENT AND RADIATION THERAPY IN LYMPHOMAS</strong>&lt;br&gt;T.M. Illidge, Manchester (UK)</td>
</tr>
<tr>
<td>15:15</td>
<td></td>
<td><strong>IMMUNOMODULATORY TREATMENT, ALONE OR IN COMBINATION WITH OTHER TREATMENT MODALITIES IN THE TREATMENT OF LYMPHOMAS</strong>&lt;br&gt;C. Moskowitz, New York, NY (USA)</td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td><strong>GENERATING AN ABSCOPAL EFFECT BY RADIOTHERAPY FOLLOWED BY CHECKPOINT INHIBITORS IN INDOLENT LYMPHOMAS</strong>&lt;br&gt;M.L. Palomba, New York, NY (USA)</td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td><strong>PANEL DISCUSSION</strong>&lt;br&gt;T.M. Illidge, Manchester (UK), C. Moskowitz, New York, NY (USA), M.L. Palomba, New York, NY (USA), M.K. Gospodarowicz, Toronto (Canada) and L. Specht, Copenhagen (Denmark)</td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td></td>
<td><strong>COFFEE BREAK - inside Aula Magna (Lugano University) for workshop attendees</strong></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td><strong>PART 2: NK/T-CELL LYMPHOMAS, AN EMERGING LYMPHOMA TYPE WITH SPECIAL ISSUES</strong>&lt;br&gt;<strong>NK/T-CELL LYMPHOMAS IN ASIA. TREATMENT PRINCIPLES. WHAT RADIATION THERAPY? WHAT CHEMOTHERAPY REGIMEN? WHEN TO COMBINE AND WHEN TO USE SINGLE MODALITY?</strong>&lt;br&gt;M. Oguchi, Tokyo (Japan)</td>
</tr>
<tr>
<td>16:45</td>
<td></td>
<td><strong>NK/T-CELL LYMPHOMAS IN THE WESTERN WORLD. EXPERIENCE WITH COMBINED MODALITY TREATMENT AT MSKCC</strong>&lt;br&gt;S.M. Horwitz, New York, NY (USA)</td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td><strong>THE BEIJING EXPERIENCE WITH RADIATION ALONE</strong>&lt;br&gt;Y.-X. Li, Beijing (China)</td>
</tr>
<tr>
<td>17:15</td>
<td></td>
<td><strong>PANEL DISCUSSION</strong>&lt;br&gt;M. Oguchi, Tokyo (Japan), S.M. Horwitz, New York, NY (USA), Y.-X. Li, Beijing (China), L. Specht, Copenhagen (Denmark) and M.K. Gospodarowicz, Toronto (Canada)</td>
</tr>
</tbody>
</table>
**Wednesday, June 14, 2017**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30 – 12:00</td>
<td>POSTER SESSION SET UP</td>
<td></td>
</tr>
<tr>
<td>Marquee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30 – 09:15</td>
<td>“MEET THE PROFESSOR” SESSIONS</td>
<td>5 parallel sessions</td>
</tr>
<tr>
<td>Room A</td>
<td>CHEMOTHERAPY-FREE TREATMENT OF INDOLENT LYMPHOMAS</td>
<td>J.W. Friedberg, Rochester, NY (USA) repeated on Thursday, June 15, in Aula Magna (Lugano University)</td>
</tr>
<tr>
<td>Room B and</td>
<td>THE 2016 UPDATED WHO CLASSIFICATION OF LYMPHOID NEOPLASIAS</td>
<td>L. Quintanilla-Martinez, Tuebingen (Germany) repeated on Friday, June 16 in Cinema Corso</td>
</tr>
<tr>
<td>Marquee</td>
<td>ROLE AND TIMING OF NEW DRUGS IN CLL</td>
<td>M. Hallek, Cologne (Germany) repeated on Friday, June 16, in Room A</td>
</tr>
<tr>
<td>Cinema Corso</td>
<td>ROLE OF STEM CELL TRANSPLANT FOR LYMPHOMA IN 2017</td>
<td>J.G. Gribben, London (UK) repeated today at 09:30 in Auditorium (Lugano University)</td>
</tr>
<tr>
<td>Auditorium</td>
<td>THE COSTS OF CARE IN HAEMATOLOGICAL CANCERS: HEALTH ECONOMIC ISSUES</td>
<td>M.F. Fey, Bern (Switzerland) offered only once</td>
</tr>
<tr>
<td>(Lugano</td>
<td></td>
<td></td>
</tr>
<tr>
<td>University)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30 – 10:15</td>
<td>5 parallel sessions</td>
<td></td>
</tr>
<tr>
<td>Room A</td>
<td>RESPONSE-ADAPTED THERAPY IN HODGKIN LYMPHOMA</td>
<td>P.W.M. Johnson, Southampton (UK) repeated on Thursday, June 15, in Cinema Corso</td>
</tr>
<tr>
<td>Room B and</td>
<td>DISEASE-ORIENTED TREATMENT OF T-CELL LYMPHOMAS</td>
<td>K. Tobinai, Tokyo (Japan) offered only once</td>
</tr>
<tr>
<td>Marquee</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cinema Corso</td>
<td>CLINICAL APPLICATIONS OF GENOME STUDIES</td>
<td>A. Younes, New York, NY (USA) repeated on Thursday, June 15, in Room B</td>
</tr>
<tr>
<td>Auditorium</td>
<td>THE ROLE OF STEM CELL TRANSPLANT FOR LYMPHOMA IN 2017</td>
<td>J.G. Gribben, London (UK)</td>
</tr>
<tr>
<td>(Lugano</td>
<td></td>
<td></td>
</tr>
<tr>
<td>University)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aula Magna</td>
<td>THE MULTIPLE FACETS OF MARGINAL ZONE LYMPHOMAS</td>
<td>M. Raderer, Vienna (Austria) repeated on Friday, June 16, in Room B</td>
</tr>
<tr>
<td>(Lugano</td>
<td></td>
<td></td>
</tr>
<tr>
<td>University)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15 – 10:35</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
<tr>
<td>Marquee</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
10:35 – 12:00

**EDUCATIONAL SYMPOSIA**

2 parallel sessions

**Room A, Cinema Corso and Aula Magna (Lugano University)**

AGGRESSIVE LYMPHOMAS
Chair: E. Campo, Barcelona (Spain)

- MOLECULAR GENETICS OF AGGRESSIVE B CELL LYMPHOMAS
  R. Dalla-Favera, New York, NY (USA)

- PATHOLOGY AND CLASSIFICATION OF AGGRESSIVE MATURE B-CELL LYMPHOMAS
  E. Campo, Barcelona (Spain)

- TREATMENT OF AGGRESSIVE B-CELL LYMPHOMAS
  S.M. Smith, Chicago, IL (USA)

**Room B and Marquee**

IMMUNOTHERAPY IN LYMPHOMAS
Chair: S.M. Ansell, Rochester, MN (USA)

- IMMUNOLOGY
  F. Caligaris-Cappio, Milan (Italy)

- CAR T-CELLS
  D.G. Maloney, Seattle, WA (USA)

- CHECKPOINT INHIBITORS
  S.M. Ansell, Rochester, MN (USA)

12:00 – 18:30

**POSTER SESSION**
(printing and delivery of the posters sponsored by Takeda Oncology)

Abstract number

- 140 - 163 PATHOLOGY AND BIOLOGY
- 164 - 177 HODGKIN LYMPHOMA
- 178 - 204 AGGRESSIVE LYMPHOMAS
- 205 - 214 MANTLE CELL LYMPHOMA
- 215 - 234 INDOLENT LYMPHOMAS
- 235 - 241 CLL
- 242 - 257 NK and T-CELL LYMPHOMAS
- 258 - 289 NEW DRUG DEVELOPMENT

12:00 – 13:00

**LUNCH TIME AND POSTER VIEWING**

Marquee

13:00 – 14:00

**OPENING OF THE CONFERENCE**

WELCOME AND INTRODUCTORY REMARKS
F. Cavalli, Bellinzona (Switzerland)

**HENRY KAPLAN MEMORIAL LECTURE AND ICML PRIZE**

Laudatio: A. Lanzavecchia, Bellinzona (Switzerland)

- 001 IMMUNOTHERAPY COMES OF AGE TO TREAT LYMPHOMAS
  R. Levy, Stanford, CA (USA)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 14:00 – 15:15 | **PLENARY SESSION**  
Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University) | Co-chairs: J.M. Vose, Omaha, NE (USA) and J.W. Friedberg, Rochester, NY (USA)                                                              |
| 14:00    | 004 INTERIM REPORT FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMAS  
F. Morschhauser, Lille (France) |                                                                                                                                            |
| 14:15    |                                                                 | Discussant: T.E. Witzig, Rochester, MN (USA)                                                                                             |
| 14:25    | 005 CRISPR-Cas9 GENETIC SCREENS UNCOVER A B CELL RECEPTOR-MYD88 SUPERPATHWAY IN DIFFUSE LARGE B CELL LYMPHOMA  
R.M. Young, Bethesda, MD (USA) |                                                                                                                                            |
| 14:40    |                                                                 | Discussant: R. Dalla-Favera, New York, NY (USA)                                                                                           |
| 14:50    | 006 BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCCLSG)  
P. Cramer, Cologne (Germany) | *Best Abstract Merit Award, sponsored by Swiss Cancer League Foundation*                                                                   |
| 15:05    |                                                                 | Discussant: D. Rossi, Bellinzona (Switzerland)                                                                                           |
| 15:15 – 15:40 | **COFFEE BREAK**  
Marquee, Cinema Corso and Aula Magna (Lugano University) |                                                                                                                                           |
| 15:40 – 16:40 | **AACR-ICML JOINT SESSION - CANCER IMMUNOTHERAPY**  
Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University) | Co-chairs: F. Cavalli, Bellinzona (Switzerland) and M. Foti, Philadelphia, PA (USA)                                                        |
| 15:40    | 007 GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)—AN INTERIM ANALYSIS  
S.J. Schuster, Philadelphia, PA (USA) |                                                                                                                                            |
| 15:55    | 008 AXICABTAGENE CILOLEUCEL (AXI-CEL; KTE-C19) IN PATIENTS WITH REFRACTORY AGGRESSIVE NON-HODGKIN LYMPHOMAS (NHL): PRIMARY RESULTS OF THE PIVOTAL TRIAL ZUMA-1  
S.S. Neelapu, Houston, TX (USA) |                                                                                                                                            |
| 16:10    | 009 WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM MALIGNANT MELANOMA?  
A.M.M. Eggermont, Villejuif (France) |                                                                                                                                            |
| 16:25    | 010 WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM LUNG CANCER?  
R. Stahel, Zurich (Switzerland) |                                                                                                                                            |
| 16:40 – 17:00 | **BREAK** |                                                                                                                                           |
17:00 – 18:00  "FOCUS ON..." SESSIONS
5 parallel sessions

Room A  CLASSICAL THERAPIES FOR FOLLICULAR LYMPHOMA
Chair: A.T. Lister, London (UK)

17:00 011 OUTCOME OF CURATIVE RADIOTHERAPY FOR LOCALISED FOLLICULAR LYMPHOMA IN THE ERA OF 18F-FDG PET-CT STAGING: AN INTERNATIONAL COLLABORATIVE STUDY ON BEHALF OF ILROG
J.L. Brady, London (UK)

17:10 012 CVP OR R-CVP GIVEN AFTER INVOLVED-FIELD RADIOTHERAPY IMPROVES PROGRESSION FREE SURVIVAL IN STAGE I-II FOLLICULAR LYMPHOMA: RESULTS OF AN INTERNATIONAL RANDOMIZED TRIAL
M.P. MacManus, Melbourne (Australia)

17:20 013 RITUXIMAB MAINTENANCE VERSUS OBSERVATION AFTER IMMUNOCHEMOTHERAPY (R-CHOP, R-MCP, R-FCM) IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RANDOMISED TRIAL OF GLSG AND OSHO
E. Hoster, Munich (Germany)

17:30 014 DURABLE BENEFIT OF RITUXIMAB MAINTENANCE POST-AUTOGRAFT IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: 12-YEAR FOLLOW-UP OF THE EBMT LYMPHOMA WORKING PARTY LYM1 TRIAL
R. Pettengell, London (UK)

17:40 015 LONG TERM RESULTS OF THE FOLL05 RANDOMIZED STUDY COMPARING R-CVP WITH R-CHOP AND R-FM AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. A FIL STUDY
S. Luminari, Reggio Emilia (Italy)

17:50 016 CAUSE OF DEATH IN FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA: A POOLED ANALYSIS OF FRENCH AND US COHORTS
C. Sarkozy, Pierre Bénite (France)

Room B and Marquee  PET/CT: VISUAL ASSESSMENT AND BEYOND
Chair: B.D. Cheson, Washington D.C. (USA)

17:00 017 PROGNOSTIC VALUE OF BASELINE TOTAL METABOLIC TUMOR VOLUME (TMTV) FOR PATIENTS WITH EARLY STAGE HODGKIN LYMPHOMA ENROLLED IN THE STANDARD ARM OF THE H10 (EORTC/LYSA/FIL) TRIAL
A. Cottereau, Paris (France)

17:10 018 BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRUCTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET-ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE
A.J. Moskowitz, New York, NY (USA)

17:20 019 CAN BASELINE PET-CT FEATURES PREDICT OUTCOMES IN ADVANCED HODGKIN LYMPHOMA? A PROSPECTIVE EVALUATION OF UK PATIENTS IN THE RATHL TRIAL (CRUK/07/033)
L.C. Pike, London (UK)

17:30 020 CLINICAL CHARACTERISTICS OF PATIENTS WITH NEGATIVE INTERIM-PET AND POSITIVE FINAL PET: DATA FROM THE PROSPECTIVE PET-ORIENTED HD0801 STUDY BY FONDAZIONE ITALIANA LINFOMI (FIL)
L. Rigacci, Florence (Italy)
17:40 021  PROGNOSTIC VALUE OF PET-CT AFTER FIRST-LINE IMMUNOCHEMOTHERAPY FOR FOLLICULAR LYMPHOMA IN THE PHASE III GALLIUM STUDY  
J. Trotman, Sydney (Australia)

17:50 022  FDG-PET AS A BIOMARKER OF RESPONSE IN DLBCL: THE HOVON 84 STUDY EXPERIENCE  
C.N. Burggraaff, Amsterdam (The Netherlands)

Cinema Corso

**CLINICO-PATHOLOGICAL CORRELATIONS**
Chair: E.S. Jaffe, Bethesda, MD (USA)

17:00 023  NON-MEDIASTINAL CASES OF GREY ZONE LYMPHOMA: A PATHOLOGICAL AND CLINICAL SERIES OF 17 CASES FROM THE LYSA  
C. Sarkozy, Pierre Bénite (France)

17:10 024  **FOXP1 EXPRESSION IS INVERSELY CORRELATED WITH EZH2 MUTATION STATUS AND PREDICTS POOR FAILURE-FREE SURVIVAL IN FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB AND CHEMOTHERAPY**  
A. Mottok, Vancouver (Canada)

17:20 025  ELEVATED EXPRESSION OF LAG3 IS ASSOCIATED WITH POOR OUTCOME IN PATIENTS WITH DLBCL TREATED WITH R-CHOP  
C. Keane, Woolloongabba (Australia)

17:30 026  CELL OF ORIGIN COMBINED WITH CNS INTERNATIONAL PROGNOSTIC INDEX IMPROVES IDENTIFICATION OF DLBCL PATIENTS WITH HIGH CNS RELAPSE RISK AFTER INITIAL IMMUNOCHEMOTHERAPY  
M. Klanova, Prague (Czech Republic)

17:40 027  **NKP46 EXPRESSION IS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER IN PRIMARY GASTROINTESTINAL T-CELL LYMPHOPROLIFERATIONS. A CELAC NETWORK STUDY**  
M. Cheminant, Paris (France)

17:50 028  ADULT PATIENTS WITH CAEBV-LIKE FEATURES: A DISTINCT SUBTYPE OF EBSTEIN-BARR VIRUS POSITIVE T/NK-CELL LYMPHOPROLIFERATIVE DISORDER  
K. Kawamoto, Kurume (Japan)

Auditorium
(Lugano University)

**NOVEL ANTI-LYMPHOMA DRUGS**
Chair: T.E. Witzig, Rochester, MN (USA)

17:00 029  PHARMACOLOGICAL ACTIVITY OF CB-103 IN HAEMATOLOGICAL MALIGNANCIES – AN ORAL PAN-NOTCH INHIBITOR WITH A NOVEL MODE OF ACTION  
D. Weber, Basel (Switzerland)

17:10 030  ANTI-TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B-CELL NON-HODGKIN LYMPHOMA  
P. Pérez-Galán, Barcelona (Spain)

17:20 031  A NEW BCL-2 INHIBITOR (S55746/BCL201) AS MONOTHERAPY IN PATIENTS WITH RELapsed OR REFRACTORY NON-HODGKIN LYMPHOMA: PRELIMINARY RESULTS OF THE FIRST-IN-HUMAN STUDY  
S. Le Gouill, Nantes (France)

17:30 032  PHASE I STUDY OF IPH4102, ANTI-KIR3DL2 MAB, IN RELAPSED/REFRACTORY CUTANEOUS T-CELL LYMPHOMAS (CTCL): DOSE-ESCALATION SAFETY, BIOMARKER AND CLINICAL ACTIVITY RESULTS  
Y.H. Kim, Stanford, CA (USA)
17:40 033  A PHASE 1 STUDY OF THE ANTI-CD37 ANTIBODY-DRUG CONJUGATE AGS67E IN ADVANCED LYMPHOID MALIGNANCIES. INTERIM RESULTS
A. Sawas, New York, NY (USA)

17:50 034  FIRST CLINICAL RESULTS OF ADCT-402, A NOVEL PYRROLOBENZODIAZEPINE-BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B-CELL LINEAGE NHL
B.S. Kahl, St. Louis, MO (USA)

Aula Magna (Lugano University)  CHEMOTHERAPY-FREE COMBINATIONS
Chair: S.M. Smith, Chicago, IL (USA)

17:00 035  FINAL RESULTS OF CALGB 50803 (ALLIANCE): A PHASE 2 TRIAL OF LENALIDOMIDE PLUS RITUXIMAB IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
P. Martin, New York, NY (USA)

17:10 036  L-MIND: MOR208 COMBINED WITH LENALIDOMIDE (LEN) IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R-R DLBCL) – A SINGLE-ARM PHASE II STUDY
G. Salles, Lyon (France)

17:20 037  A PHASE II LYSA STUDY OF OBINUTUZUMAB COMBINED WITH LENALIDOMIDE FOR RELAPSED OR REFRACTORY FOLLICULAR B-CELL LYMPHOMA
F. Morschhauser, Lille (France)

17:30 038  PHASE IB STUDY OF CC-122 IN COMBINATION WITH OBINUTUZUMAB (GA101): RELAPSED OR REFRACTORY (R/R) PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMAS (NHL)
J.M. Michot, Villejuif (France)

17:40 039  PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA
C. Batlevi, New York, NY (USA)

17:50 040  UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF TGR-1202 IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MCL OR CLL
M.S. Davids, Boston, MA (USA)

Thursday, June 15, 2017

08:00 – 08:45  MEET THE PROFESSOR SESSIONS
5 parallel sessions

Room A  MANAGEMENT OF AGGRESSIVE LYMPHOMAS IN VERY ELDERLY PATIENTS
C. Thieblemont, Paris (France)
repeated on Friday, June 16, in Aula Magna (Lugano University)

Room B and Marquee  CLINICAL APPLICATIONS OF GENOME STUDIES
A. Younes, New York, NY (USA)

Cinema Corso  RESPONSE-ADAPTED THERAPY IN HODGKIN LYMPHOMA
P.W.M. Johnson, Southampton (UK)
ALCL AND PTCL: WHAT CAN PEDIATRIC AND ADULT ONCOLOGISTS LEARN FROM EACH OTHER?
L. Bruglières, Villejuif (France) and F. D’Amore, Aarhus (Denmark)
offered only once

CHEMOTHERAPY-FREE TREATMENT OF INDOLENT LYMPHOMAS
J.W. Friedberg, Rochester, NY (USA)

08:30 – 18:30
POSTER SESSION

09:00 – 10:30
"CASE DISCUSSION" SESSIONS: California vs Germany
4 parallel sessions

HODGKIN LYMPHOMA
Chair: C. Moskowitz, New York, NY (USA)
Discussants: R.H. Advani, Stanford vs P. Borchmann, Cologne

T-CELL LYMPHOMAS
Chair: J.M. Vose, Omaha, NE (USA)
Discussants: L.C. Pinter-Brown, Orange vs G. Wulf, Goettingen

PEDiatric and ADOLESCENT LYMPHOMAS
Chair: W. Wössmann, Giessen (Germany)
Discussants: C. Bollard, Washington, DC vs B. Burkhardt, Muenster

RADIOThERAPY FOR LYMPHOMAS
Chair: L. Specht, Copenhagen (Denmark)
Discussants: R.T. Hoppe, Stanford vs G. Mikhaeel, London (UK)

SESSION 1 – LYMPHOMA BIOLOGY
Co-chairs: R. Küppers, Essen (Germany) and M.A. Shipp, Boston, MA (USA)

09:00 041 GB VIRUS-C (GBV-C) INFECTION AND RISK OF LYMPHOMA: A CASE-CONTROL STUDY FROM NORTH AMERICA
A. Fama, Rochester, MN (USA)

09:15 042 DRUG PERTURBATION BASED STRATIFICATION OF LYMPHOPROLIFERATIVE DISORDERS
S. Dietrich, Heidelberg (Germany)

09:30 043 ETS1 POSITIVELY REGULATES FAIM3 IN ACTIVATED B CELL-LIKE (ABC) DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
V. Priebe, Bellinzona (Switzerland)

09:45 044 NOTCH1 MUTATED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE CHARACTERIZED BY A MYC-RELATED OVEREXPRESSION OF NUCLEOPHOSMIN-1 AND RIBOSOME ASSOCIATED COMPONENTS
F. Pozzo, Aviano (Italy)

10:00 045 ACTIVATION OF RHOA-VAV1 SIGNALING IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
M. Sakata-Yanagimoto, Ibaraki (Japan)

10:15 046 TARGETABLE FUSIONS OF THE FRK TYROSINE KINASE IN ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA
R.L. Boddicker, Rochester, MN (USA)
10:30 – 11:00
Marquee

COFFEE BREAK

11:00 – 12:00
Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

SESSION 2 – PRIMARY MEDIASTINAL B-CELL LYMPHOMA
Co-chairs: A.J. Davies, Southampton (UK) and G.S. Nowakowski, Rochester, MN (USA)

11:00 047
MOLECULAR CLASSIFICATION OF PRIMARY MEDIASTINAL LARGE B CELL LYMPHOMA USING FORMALIN-FIXED, PARAFFIN-EMBEDDED TISSUE SPECIMENS – AN LLMPP PROJECT
A. Mottok, Vancouver (Canada)

11:15 048
METABOLIC HETEROGENEITY OF BASELINE 18-FDG PET-CT SCAN PREDICTS OUTCOME IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA
L. Ceriani, Bellinzona (Switzerland)

11:30 049
OUTCOMES OF ADULTS, ADOLESCENTS, AND CHILDREN WITH PRIMARY MEDIASTINAL B-CELL LYMPHOMA TREATED WITH DOSE-ADJUSTED EPOCH-R THERAPY: A MULTICENTER RETROSPECTIVE ANALYSIS
L.G. Roth, New York, NY (USA)

11:45 050
EFFICACY AND SAFETY OF PEMBROLIZUMAB IN RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (rrPMBCL): INTERIM ANALYSIS OF THE KEYNOTE-170 PHASE 2 TRIAL
P.L. Zinzani, Bologna (Italy)

12:00 – 13:00
Marquee

LUNCH TIME AND POSTER VIEWING
from 12:30 to 13:00 authors in front of their poster for discussion with attendees

13:00 – 13:45
Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)

GIANNI BONADONNA MEMORIAL LECTURE 🔔
Chair: R. Dalla-Favera, New York, NY (USA)
sponsored by American Association for Cancer Research – AACR

002
GENETIC SIGNATURES AND TARGETABLE PATHWAYS IN LYMPHOID MALIGNANCIES
M.A. Shipp, Boston, MA (USA)

13:15 – 16:45
Auditorium (Lugano University)

WORKSHOP - CONTEMPORARY LYMPHOMA TREATMENT: RADIATION THERAPY ISSUES
Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and J. Yahalom, New York, NY (USA)
Organized by International Lymphoma Radiation Oncology Group – ILROG
open to all 14-ICML attendees

MY INDICATIONS FOR RADIATION THERAPY IN THE PRIMARY TREATMENT OF HODGKIN AND NON HODGKIN LYMPHOMAS

13:15
A.K. Ng, Boston, MA (USA)

13:30
C. Thieblemont, Paris (France)

13:45
U. Ricardi, Turin (Italy)

14:00
Case oriented discussion: A.K. Ng, Boston (USA), C. Thieblemont, Paris (France), U. Ricardi, Turin (Italy), J. Yahalom, New York, NY (USA) and M.K. Gospodarowicz, Toronto (Canada)

14:15 – 14:25
BREAK

MY INDICATIONS FOR RADIATION THERAPY IN RELAPSED/REFRACTORY HODGKIN AND NON HODGKIN LYMPHOMAS

14:25
J. Yahalom, New York, NY (USA)

14:40
G. Salles, Lyon (France)

14:55
G. Mikhaeel, London (UK)
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:10</td>
<td>Case oriented discussion: J. Yahalom, New York, NY (USA), G. Salles, Lyon (France), G. Mikhaeel, London (UK) and M.K. Gospodarowicz, Toronto (Canada)</td>
<td></td>
</tr>
<tr>
<td>15:25 – 15:45</td>
<td><strong>COFFEE BREAK</strong> - inside Auditorium (Lugano University) for workshop attendees</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>APPROACHES TO REDUCE LATE EFFECTS OF LYMPHOMA TREATMENT</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>B.S. Dabaja, Houston, TX (USA): IS PROTON THERAPY THE ANSWER?</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>D. Hodgson, Toronto (Canada): STRATEGIES TO REDUCE THE RISK OF SECOND MALIGNANCIES</td>
<td></td>
</tr>
<tr>
<td>16:15</td>
<td>L. Specht, Copenhagen (Denmark): STRATEGIES TO REDUCE THE RISK OF CARDIOVASCULAR LATE EFFECTS</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Discussion: B.S. Dabaja, Houston, TX (USA), D. Hodgson, Toronto (Canada), L. Specht, Copenhagen (Denmark), J. Yahalom, New York, NY (USA) and M.K. Gospodarowicz, Toronto (Canada)</td>
<td></td>
</tr>
<tr>
<td>13:45 – 15:15</td>
<td><strong>SESSION 3 – HODGKIN LYMPHOMA</strong></td>
<td></td>
</tr>
<tr>
<td>Room A, B, Marquee, Cinema Corso and Aula Magna (Lugano University)</td>
<td>Co-chairs: V. Diehl, Cologne (Germany) and A. Pavlovsky, Buenos Aires (Argentina)</td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td>RESTORE &amp; TARGET: A CONCEPTUALLY NOVEL TREATMENT APPROACH TO CLASSICAL HODGKIN’S LYMPHOMA</td>
<td>C. Schmitt, Berlin (Germany)</td>
</tr>
<tr>
<td>14:00</td>
<td>GENOTYPING OF CLASSICAL HODGKIN LYMPHOMA ON THE LIQUID BIOPSY</td>
<td>A. Bruscaggin, Bellinzona (Switzerland)</td>
</tr>
<tr>
<td>14:15</td>
<td>eBEACOPP WITH OR WITHOUT RITUXIMAB IN INTERIM-PET-POSITIVE ADVANCED-STAGE HODGKIN LYMPHOMA: UPDATED RESULTS OF THE INTERNATIONAL, RANDOMIZED PHASE 3 GHSG HD18 TRIAL</td>
<td>P. Borchmann, Cologne (Germany)</td>
</tr>
<tr>
<td>14:30</td>
<td>RESPONSE-ADJUSTED THERAPY FOR ADVANCED HODGKIN LYMPHOMA (RATHL) TRIAL: LONGER FOLLOW UP CONFIRMS EFFICACY OF DE-ESCALATION AFTER A NEGATIVE INTERIM PET SCAN (CRUK/07/033)</td>
<td>J. Trotman, Concord (Australia)</td>
</tr>
<tr>
<td>14:45</td>
<td>BLOCKADE OF THE PD-1 CHECKPOINT WITH ANTI–PD-L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (cHL)</td>
<td>R. Chen, Duarte, CA (USA)</td>
</tr>
<tr>
<td>15:00</td>
<td>COMBINED RISK OF SECOND MALIGNANT NEOPLASMS AND CARDIOVASCULAR DISEASE IN LONG-TERM HODGKIN LYMPHOMA SURVIVORS</td>
<td>B.M. Aleman, Amsterdam (The Netherlands)</td>
</tr>
<tr>
<td>15:15 – 15:30</td>
<td><strong>COFFEE BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>Marquee, Cinema Corso and Aula Magna (Lugano University)</td>
<td></td>
</tr>
</tbody>
</table>
15:30 – 17:00  
2 parallel sessions

15:30 – 17:00  
Room A, Cinema Corso and Aula Magna (Lugano University)

SESSION 4 – TARGETING THE BCR PATHWAYS  
Co-chairs: J.F. Seymour, Melbourne (Australia) and C. Thieblemont, Paris (France)

15:30 057  
CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM A PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA  
G. Lenz, Muenster (Germany)

15:45 058  
DYNAMO: A PHASE 2 STUDY DEMONSTRATING THE CLINICAL ACTIVITY OF DUVELISIB IN PATIENTS WITH DOUBLE-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA  
P.L. Zinzani, Bologna (Italy)

16:00 059  
BRUTON’S TYROSINE KINASE (BTK) INHIBITOR BGB-3111 DEMONSTRATES HIGH VERY GOOD PARTIAL RESPONSE (VGPR) RATE IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA (WM)  
J. Trotman, Concord (Australia)

16:15 060  
IBRUTINIB IN RELAPSE OR REFRACTORY PRIMARY CNS AND VITREO-RETINAL LYMPHOMA. RESULTS OF THE PRIMARY END-POINT OF THE LOC PHASE II STUDY FROM THE LYSA AND THE FRENCH LOC NETWORK  
C. Soussain, Saint-Cloud (France)

16:30 061  
TAK-659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT-3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE-ESCALATION AND EXPANSION COHORTS OF A PHASE 1 STUDY  
J. Kaplan, Chicago, IL (USA)

16:45 062  
THE DUAL SYK/JAK INHIBITOR CERDULATINIB DEMONSTRATES RAPID TUMOR RESPONSES IN A PHASE 2 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL MALIGNANCIES  
P.A. Hamlin, Basking Ridge, NJ (USA)

15:30 – 17:00  
Room B and Marquee

SESSION 5 – T-CELL LYMPHOMAS  
Co-chairs: K. Tobinai, Tokyo (Japan) and J.M. Vose, Omaha, NE (USA)

15:30 063  
GENE EXPRESSION PROFILING USING A RTMLPA ASSAY ALLOWS FOR AN ACCURATE CLASSIFICATION OF PERIPHERAL T-CELL LYMPHOMA AND HIGHLIGHTS NOVEL SUBGROUPS WITHIN PTCLs-NOS  
P. Ruminy, Rouen (France)

15:45 064  
CHOP VERSUS GEM-P IN THE FIRST-LINE TREATMENT OF T-CELL LYMPHOMA: INITIAL RESULTS OF THE UK NRCl PHASE II RANDOMISED CHEMO-T TRIAL  
M. Gleeson, Sutton (UK)

16:00 065  
ROLE OF UP-FRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN PERIPHERAL T-CELL LYMPHOMA: A PROPENSITY SCORE MATCHING ANALYSIS OF PATIENTS FROM LYSA CENTERS  
G. Fossard, Pierre Bénite (France)

16:15 066  
BRENTUXIMAB VEDOTIN VS PHYSICIAN’S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION  
Y.H. Kim, Stanford, CA (USA)
16:30 067 IMPROVED SURVIVAL OUTCOMES FOR PATIENTS WITH EXTRA-NODAL NK/T LYMPHOMA: DATA FROM 140 PATIENTS PROSPECTIVELY REGISTERED IN THE INTERNATIONAL T-CELL PROJECT
C.P. Fox, Nottingham (UK)

16:45 068 GAD-M REGIMEN FOR NEWLY DIAGNOSED EXTRANODAL NK/T CELL LYMPHOMA: ANALYSIS OF EFFICACY AND SAFETY FROM PHASE II STUDY (NCT 01991158)
Z. Li, Guang Zhou (China)

17:00-17:15 BREAK

17:15-18:15 “FOCUS ON…” SESSIONS
5 parallel sessions

Room A

TARGETING CD30 IN HODGKIN LYMPHOMA
Chair: A. Engert, Cologne (Germany)

17:15 069 RESULTS OF A PHASE II STUDY OF BRENTUXIMAB VEDOTIN IN THE FIRST LINE TREATMENT OF HODGKIN LYMPHOMA PATIENTS CONSIDERED UNSUITABLE FOR STANDARD CHEMOTHERAPY (BREVITY)
A. Gibb, Manchester (UK)

17:25 070 BRENTUXIMAB VEDOTIN CONSOLIDATION TO REDUCE RADIATION USE IN PATIENTS WITH LIMITED STAGE NON-BULKY HODGKIN LYMPHOMA: AN UPDATE FROM A PHASE 2 CLINICAL TRIAL
S.I. Park, Charlotte, NC (USA)

17:35 071 RESULTS OF A MULTICENTRE UK-WIDE STUDY EVALUATING THE EFFICACY OF BRENTUXIMAB VEDOTIN IN RELAPSED, REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN THE PRE-TRANSPLANT NAIVE SETTING
T.A. Eyre, Oxford (UK)

17:45 072 BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: A RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY
A. Bazarbachi, Beirut (Lebanon)

17:55 073 SAFETY AND EFFICACY OF COMBINATION OF BRENTUXIMAB VEDOTIN AND NIVOLUMAB IN RELAPSED / REFRACTORY HODGKIN LYMPHOMA: A TRIAL OF THE ECOG-ACRIN CANCER RESEARCH GROUP (E4412)
C.S. Diefenbach, New York, NY (USA)

18:05 074 INTERIM RESULTS FROM A PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA
A.F. Herrera, Duarte, CA (USA)

Room B and Marquee

NOVEL ANTI-LYMPHOMA STRATEGIES
Chair: P.W.M. Johnson, Southampton (UK)

17:15 075 CLARITHROMYCIN AS A “REPURPOSING DRUG” AGAINST LYMPHOMAS: SAFETY AND EFFICACY PROFILES IN 55 PATIENTS WITH EXTRANODAL MARGINAL ZONE LYMPHOMA (EMZL)
A.J. Ferreri, Milan (Italy)

17:25 076 A PHASE 1 STUDY OF PRALATREXATE PLUS ROMIDEPSIN REVEALS MARKED ACTIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) PERIPHERAL T-CELL LYMPHOMA (PTCL)
J.E. Amengual, New York, NY (USA)
17:35  077  CANADIAN CANCER TRIALS GROUP (CCTG) LY.17: A RANDOMIZED PHASE II STUDY EVALUATING NOVEL SALVAGE THERAPY PRE-AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RR-DLBCL) - OUTCOME OF IBRUTINIB + R-GDP
J. Kuruvilla, Kingston (Canada)

17:45  078  EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCI RIALTO TRIAL
A. Pettitt, Liverpool (UK)

17:55  079  VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF A PHASE I STUDY
L.J. Swinnen, Baltimore, MD (USA)

18:05  080  POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
H. Tilly, Rouen (France)

Cinema Corso

CLINICO-GENETIC RISK MODELS
Chair: P. Gaulard, Créteil (France)

17:15  081  APPLICATION OF A GENE EXPRESSION-BASED MODEL IN COMBINATION WITH FDG-PET IMAGING TO PREDICT TREATMENT RESPONSE IN ADVANCED HODGKIN LYMPHOMA IN THE RATHL STUDY (CRUK/07/033)
C.H. Burton, Leeds (UK)

17:25  082  THE 23-GENE GENE EXPRESSION-BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL
D.W. Scott, Vancouver (Canada)

17:35  083  GENE MUTATIONS AND COPY NUMBER ALTERATIONS (CNA) PREDICT FOR EARLY FAILURE IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH R-CHOP
I. Dlouhy, Barcelona (Spain)

17:45  084  KMT2D AND TP53 MUTATIONS PREDICT POOR PFS AND OS IN MANTLE CELL LYMPHOMA RECEIVING HIGH-DOSE THERAPY AND ASCT: THE FONDAZIONE ITALIANA LINFOMI (FIL) MCL0208 PHASE III TRIAL
S. Ferrero, Turin (Italy)

17:55  085  BASELINE CIRCULATING CELL-FREE DNA LOAD IS RELATED TO, BUT ADDS PROGNOSTIC VALUE TO METABOLIC TUMOR BURDEN MEASURED BY FDG PET/CT IN FOLLICULAR LYMPHOMA
M.H. Delfau-Larue, Creteil (France)

18:05  086  EVALUATION OF CLINICOGENETIC RISK MODELS FOR OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN THE PRIMA TRIAL
S. Huet, Pierre Bénite (France)

Auditorium
(Lugano University)

ONGOING TRIALS
Chair: M. Dreyling, Munich (Germany)

17:15  OT01  ROBUST: PHASE III RANDOMIZED STUDY OF LENALIDOMIDE/R-CHOP VS PLACEBO/R-CHOP IN UNTREATED ABC-TYPE DIFFUSE LARGE B-CELL LYMPHOMA AND FEASIBILITY OF CELL OF ORIGIN SUBTYPING
A. Chiappella, Turin (Italy)
OT02 17:25 PHASE II STUDY OF DURVALUMAB (ANTI–PD-L1) COMBINED WITH EITHER R-CHOP OR LENALIDOMIDE AND R-CHOP IN PREVIOUSLY UNTREATED, HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA
U. Jäger, Vienna (Austria)

OT03 17:35 CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA
L. Nayak, Boston, MA (USA)

OT04 17:45 MCL-R2 ELDERLY: A PHASE III STUDY OF THE EUROPEAN MCL NETWORK ASSESSING EFFICACY OF ALTERNATING IMMUNOCHEMOTHERAPY (R-CHOP / R-HAD) AND A RITUXIMAB-LENALIDOMIDE MAINTENANCE
V. Ribrag, Villejuif (France)

Aula Magna (Lugano University) LYMPHOMA IN THE ELDERLY
Chair: U. Vitolo, Turin (Italy)

OT05 17:55 PHASE 3 STUDY OF IBRUTINIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (MCL)
C.S. Tam, Melbourne (Australia)

OT06 18:05 A HEAD-TO-HEAD PHASE 3 STUDY COMPARING BGB-3111 AND IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA
C. Buske, Ulm (Germany)

LYMPHOMA IN THE ELDERLY

087 17:15 HIGHER AGE IS ASSOCIATED WITH INCREASED MUTATIONAL BURDEN BUT DOES NOT IMPACT TREATMENT EFFICACY IN FOLLICULAR LYMPHOMA
S. Alig, Munich (Germany)

088 17:25 LOW NK CELL COUNT AT DIAGNOSIS IS ASSOCIATED WITH SHORTER PFS IN ELDERLY PATIENTS WITH DLBCL TREATED WITH RCHOP AND RANDOMIZED FOR LENALIDOMIDE MAINTENANCE. A LYSA STUDY
M.H. Delfau-Larue, Creteil (France)

089 17:35 CHARACTERISTICS, TREATMENT, AND OUTCOMES OF ≥ 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP
O. Al-Sawaf, Cologne (Germany)

090 17:45 UNMET MEDICAL NEEDS IN HODGKIN LYMPHOMA WITH SPECIAL FOCUS ON THE ELDERLY – A POPULATION-BASED STUDY OF PATIENTS DIAGNOSED IN SWEDEN 1973-2014
M. Björklund, Stockholm (Sweden)

091 17:55 TREATMENT STRATEGIES AND OUTCOMES IN DIFFUSE LARGE B-CELL LYMPHOMA OF THE ELDERLY: A DANISH POPULATION-BASED COHORT STUDY OF 1,011 PATIENTS
M.B. Juul, Odense (Denmark)

092 18:05 REMARC STUDY: CORRELATION OF LYMPHOMA PD AND DEATH AND HEALTH-RELATED QOL WITH MAINTENANCE LENALIDOMIDE VS PLACEBO IN ELDERLY DLBCL PATIENT RESPONDERS TO R-CHOP
C. Thieblemont, Paris (France)
Friday, June 16, 2017

08:00 – 08:45  **MEET THE PROFESSOR SESSIONS**
*5 parallel sessions*

Room A  
ROLE AND TIMING OF NEW DRUGS IN CLL  
M. Hallek, Cologne (Germany)

Room B and Marquee  
THE MULTIPLE FACETS OF MARGINAL ZONE LYMPHOMAS  
M. Raderer, Vienna (Austria)

Cinema Corso  
THE 2016 UPDATED WHO CLASSIFICATION OF LYMPHOID NEOPLASIAS  
L. Quintanilla-Martinez, Tuebingen (Germany)

Auditorium (Lugano University)  
LATE SEQUELAE IN HODGKIN LYMPHOMA SURVIVORS  
F.E. Van Leeuwen, Amsterdam (The Netherlands)  
*offered only once*

Aula Magna (Lugano University)  
MANAGEMENT OF AGGRESSIVE LYMPHOMAS IN VERY ELDERLY PATIENTS  
C. Thieblemont, Paris (France)

08:30 – 18:30  **POSTER SESSION**

09:00 – 10:30  **“CASE DISCUSSION” SESSIONS: California vs Germany**
*4 parallel sessions*

Room A  
AGGRESSIVE LYMPHOMAS  
Chair: S. Le Gouill, Nantes (France)  
Discussants: S. De Vos, Santa Monica vs G. Lenz, Muenster

Cinema Corso  
INDOLENT LYMPHOMAS  
Chair: A. Lopez-Guillermo, Barcelona (Spain)  
Discussants: T. J. Kipps, La Jolla vs M. Dreyling, Munich

Auditorium (Lugano University)  
CLL  
Chair: J.G. Gribben, London (UK)  
Discussants: S.M. O’Brien, Orange vs S. Stilgenbauer, Ulm

Aula Magna (Lugano University)  
DIFFICULT PATHOLOGICAL CASES  
Chair: M. Ghielmini, Bellinzona (Switzerland)  
Presenters: E. Campo, Barcelona (Spain), S. Dirnhofer, Basel (Switzerland), L. Quintanilla-Martinez, Tuebingen (Germany)  
Discussants: S.T. Rosen, Duarte vs U. Dührsen, Essen

09:00 – 10:30  **SESSION 6 – LYMPHOMA GENOMICS**

Room B and Marquee  
Co-chairs: A. Melnick, New York, NY (USA) and W.-L. Zhao, Shanghai (China)

09:00  **093**  
A SINGLE-CELL BASED MODEL EXPLAINS PATTERNS OF CLONAL EVOLUTION IN PRIMARY AND RELAPSED FOLLICULAR LYMPHOMA  
M. Löffler, Leipzig (Germany)

09:15  **094**  
FULL TRANSCRIPTOME SEQUENCING OF SORTED HODGKIN AND REED-STERNBERG CELLS REVEALS PLASMACYTIC DIFFERENTIATION, INSIGHTS INTO MECHANISMS OF ONCOGENESIS AND IMMUNE EVASION  
M. Roshal, New York, NY (USA)
09:30 095 PROFILING OF DNA METHYLATION IN EPIDEMIOLOGICAL AND CLINICAL SUBGROUPS OF BURKITT LYMPHOMA IN THE FRAMEWORK OF THE MMML, ICGC AND BLUEPRINT CONSORTIA
R. Wagener, Ulm (Germany)

09:45 096 MUTATIONAL SIGNATURES IN GERMINAL CENTER DERIVED B-CELL LYMPHOMAS FROM ADULT PATIENTS ANALYZED IN THE ICGC MMML-SEQ CONSORTIUM
D. Huebschmann, Heidelberg (Germany)

10:00 097 CROSS-PLATFORM VALIDATION OF GENE EXPRESSION PROFILING (GEP) BASED CELL OF ORIGIN (COO) CLASSIFICATION IN A CLINICAL LABORATORY SETTING
S. Barrans, Leeds (UK)

10:15 098 THE LANDSCAPE OF SOMATIC MUTATIONS OF PRIMARY CUTANEOUS DIFFUSE LARGE B-CELL LYMPHOMA, LEG-TYPE
F. Jardin, Rouen (France)

10:30 – 10:50 COFFEE BREAK

10:50 – 12:05 SESSION 7 – ADVANCES IN CLL
Co-chairs: N. Chiorazzi, Manhasset, NY (USA) and B. Eichhorst, Cologne (Germany)

10:50 099 INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49d: CLINICAL RELEVANCE
E. Tissino, Aviano (Italy)

11:05 100 INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH-RISK PROGNOSTIC FACTORS
T.J. Kipps, La Jolla, CA (USA)

11:20 101 UBLITUXIMAB AND IBRUTINIB FOR PREVIOUSLY TREATED GENETICALLY HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: RESULTS OF THE GENUINE PHASE 3 STUDY
A. Mato, Philadelphia, PA (USA)

11:35 102 CHEMO-FREE TRIPLET COMBINATION OF TGR-1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL
L.J. Nastoupil, Houston, TX (USA)

11:50 103 SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB-3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
C.S. Tam, Melbourne (Australia)

12:05 – 13:00 LUNCH TIME AND POSTER VIEWING
from 12:30 to 13:00 authors in front of their poster for discussion with attendees

13:00 – 13:45 JOHN ULMANN MEMORIAL LECTURE
Chair: E. Campo, Barcelona (Spain)

sponsored by European School of Oncology – ESO
GENOMES IN TRANSIT: WHAT MULTI-OMICS CAN TELL US ON LYMPHOMAS
R. Siebert, Ulm (Germany)

3 parallel sessions

13:45 – 15:15
SESSION 8 – FOLLICULAR LYMPHOMA
Co-chairs: B.S. Kahl, St. Louis, MO (USA) and E. Kimby, Stockholm (Sweden)

13:45  104  GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA
S. Huet, Pierre Bénite (France)

14:00  105  THE RISK OF TRANSFORMATION OF FOLLICULAR LYMPHOMA “TRANSFORMED” BY RITUXIMAB. THE ARISTOTLE STUDY PROMOTED BY THE EUROPEAN LYMPHOMA INSTITUTE
M. Federico, Modena (Italy)

14:15  106  PROGNOSTIC MODEL FOR HIGH TUMOR BURDEN FOLLICULAR LYMPHOMA INCLUDING BASELINE TOTAL METABOLIC TUMOR VOLUME AND END INDUCTION PET: A POOLED ANALYSIS FROM LYSA AND FIL TRIALS
A. Cottereau, Paris (France)

14:30  107  IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA IN THE RANDOMISED PHASE III GALLIUM STUDY: ANALYSIS BY CHEMOTHERAPY REGIMEN
W. Hiddemann, Munich (Germany)

14:45  108  COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL LYMPHOMA (CHRONOS-1)
M. Dreyling, Munich (Germany)

15:00  109  HIGH RESPONSE RATES WITH PEMBROLIZUMAB IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA: INTERIM RESULTS OF AN ON OPEN-LABEL, PHASE II STUDY
L.J. Nastoupil, Houston, TX (USA)

14:15 – 17:15
IBSA FOUNDATION SPECIAL FORUM - BASIC MECHANISMS OF CANCER IMMUNOTHERAPY
Chair: A. Alimonti, Bellinzona (Switzerland)
Organized by IBSA Foundation for Scientific Research
open to all 14-ICML attendees, appreciated pre-registration at www.ibsafoundation.org (free session)

14:15  WELCOME
S. Misiti, Lugano (Switzerland)

14:20  INTRODUCTION
A. Alimonti, Bellinzona (Switzerland)

14:30  IMMUNOTHERAPY HAS COME OF AGE
R. Levy, Stanford, CA (USA)

15:00  IMMUNOGENIC CELL DEATH: EXPLAINING THE SUCCESS OF CANCER THERAPIES
G. Kroemer, Paris (France)

15:30 – 16:00  COFFEE BREAK - inside Auditorium (Lugano University) for attendees
WHY THE IMMUNE RESPONSE IN LYMPHOMA IS INADEQUATE
F. Caligaris-Cappio, Milan (Italy)

PRE-CLINICAL DEVELOPMENT OF NOVEL COMBINATORIAL THERAPIES AGAINST MYC/BCL2 DOUBLE-HIT LYMPHOMA
B. Amati, Milan (Italy)

14:15 – 17:05
UCLI-ICML JOINT SESSION - NATURAL KILLER / T-CELL (NK/T-CELL) LYMPHOMA
Aula Magna (Lugano University)
Co-chairs: J.M. Vose, Omaha, NE (USA), J. Zhu, Beijing (China) and Y.-K. Shi, Beijing (China)
Organized in collaboration with Union of Chinese Lymphoma Investigators - UCLI

14:15  110  NON-CANONICAL ROLE OF EZH2 IN NK / T-CELL LYMPHOMA
W.-J. Chng, Singapore (Singapore)

14:30  111  EBV-ASSOCIATED NODAL T AND NK-CELL LYMPHOMA SHOWS DISTINCT MOLECULAR SIGNATURE AND COPY NUMBER CHANGES
W.-J. Chng, Singapore (Singapore)

14:45  112  NK/T-CELL LYMPHOMA: WHEN PATIENTS MEET OMICS
W.-L. Zhao, Shanghai (China)

15:00  113  TREATMENT OF EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE (ENKTL)
W.S. Kim, Seoul (South Korea)

15:15 – 15:35  COFFEE BREAK - inside Aula Magna (Lugano University) for attendees

15:35  114  FIRST-LINE L-ASPARAGINASE-BASED CHEMOTHERAPY PLUS RADIOTHERAPY IS ACTIVE IN STAGE III EXTRANODAL NK/T-CELL LYMPHOMA: RESULTS FROM PEKING UNIVERSITY CANCER HOSPITAL
Y.-Q. Song, Beijing (China)

15:50  115  CURRENT TREATMENT FOR NK/T CELL LYMPHOMA: SUN YAT-SEN UNIVERSITY CANCER CENTER EXPERIENCE, CHINA
H.-Q. Huang, Guangzhou (China)

16:05  116  MOLECULAR CHARACTERIZATION OF EXTRANODAL NATURAL KILLER (NK)/T-CELL LYMPHOMAS, NASAL TYPE FROM LATIN AMERICA
L. Quintanilla-Martinez, Tuebingen (Germany)

16:20  117  NK/T-CELL LYMPHOMA, THE FRENCH EXPERIENCE
A. Jaccard, Limoges (France)

16:35  COMMENTS
M. Federico, Modena (Italy), W.-Q. Jiang, Guangzhou (China) and X.-P. Lu, Shenzhen (China)

15:15 – 15:35  COFFEE BREAK

15:35 – 15:50  DESIGN OF FUTURE CLINICAL TRIALS: REPORT OF THE 14-ICML WORKSHOP
Room A, B, Marquee and Cinema Corso
Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and E. Zucca, Bellinzona (Switzerland)
A. Younes, New York, NY (USA)
SESSION 9 – AGGRESSIVE LYMPHOMAS
Co-chairs: M.K. Gospodarowicz, Toronto (Canada) and E. Zucca, Bellinzona (Switzerland)

15:50 – 17:20
Room A, B, Marquee and Cinema Corso

15:50 118  LONG-TERM SURVIVAL AND LOSS IN EXPECTANCY OF LIFE IN A POPULATION-BASED COHORT OF 7114 PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA
K.E. Smedby, Solna (Sweden)

16:05 119  R-CHOP +/- RADIOTHERAPY IN NON-BULKY LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FINAL RESULTS OF THE PROSPECTIVE RANDOMIZED PHASE III 02-03 TRIAL FROM THE LYSA/GOELAMS
T. Lamy, Rennes (France)

16:20 120  RADIOTHERAPY TO BULKY DISEASE PET-NEGATIVE AFTER IMMUNOCHEMOTHERAPY CAN BE SPARED IN ELDERLY DLBCL PATIENTS: RESULTS OF A PLANNED INTERIM ANALYSIS OF THE FIRST 187 PATIENTS WITH BULKY DISEASE TREATED IN THE OPTIMAL>60 STUDY OF THE DSHNHL
M. Pfreundschuh, Homburg (Germany)

16:35 121  DIFFERENTIAL EFFICACY OF BORTEZOMIB IN SUBTYPES OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A PROSPECTIVE RANDOMISED STUDY STRATIFIED BY TRANSCRIPTOME PROFILING: REMoDL-B
A.J. Davies, Southampton (UK)

16:50 122  PROGNOSTIC IMPACT OF BCL2 AND MYC EXPRESSION AND TRANSLOCATION IN UNTREATED DLBCL: RESULTS FROM THE PHASE III GOYA STUDY
U. Vitolo, Turin (Italy)

17:05 123  RISK-ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF A MULTICENTER PROSPECTIVE PHASE II STUDY OF DA-EPOCH-R
K. Dunleavy, Bethesda, MD (USA)

17:30 – 18:45
Marquee

FAREWELL APERO

Saturday, June 17, 2017

08:00 – 10:30
Room 156
(Lugano University)

SPECIAL SESSION - CONTOURING IN MODERN LYMPHOMA RADIOTHERAPY PLANNING
A.K. Berthelsen, Copenhagen (Denmark) and L. Specht, Copenhagen (Denmark)
Organized by International Lymphoma Radiation Oncology Group - ILROG and European Society for Radiotherapy and Oncology – ESTRO
Compulsory pre-registration up to 30 attendees at registration@lymphcon.ch (fee CHF 50.00)

08:30 – 10:00
2 parallel sessions

Room A

SESSION 10 – IMMUNOTHERAPIES
Co-chairs: R. Levy, Stanford, CA (USA) and D.G. Maloney, Seattle, WA (USA)

08:30 124  CD27 STIMULATION ENHANCES CD20 MAB THERAPY THROUGH ACTIVATION OF INNATE IMMUNITY
S.H. Lim, Southampton (UK)

08:45 125  NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE PHASE 2 CHECKMATE 205 TRIAL
M. Fanale, Houston, TX (USA)
09:00  126  PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE-087 STUDY  
P.L. Zinzani, Bologna (Italy)

09:15  127  A PHASE Ib STUDY EVALUATING THE SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB COMBINED WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMA (NHL)  
M.L. Palomba, New York, NY (USA)

09:30  128  HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B-NHL TREATED WITH THE CD19-DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001)  
J. Abramson, Boston, MA (USA)

09:45  129  A PHASE I TRIAL OF 19-28Z CAR T CELLS POST-HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT-ASCT) FOR RELAPSED AND REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)  
C. Sauter, New York, NY (USA)

Room B

SESSON 11 – MANTLE CELL LYMPHOMA
Co-chairs: U. Novak, Bern (Switzerland) and G. Salles, Lyon (France)

08:30  130  P53 BUT NOT SOX11 IHC HAS PROGNOSTIC VALUE INDEPENDENT OF MIPI AND KI-67 IN PROSPECTIVE TRIALS OF THE EUROPEAN-MCL NETWORK  
M. Dreyling, Munich (Germany)

08:45  131  FIRST-LINE TREATMENT OF INHL OR MCL PATIENTS WITH BR OR R-CHOP/R-CVP: RESULTS OF THE BRIGHT 5-YEAR FOLLOW-UP STUDY  
T. Hawkins, Auckland (New Zealand)

09:00  132  FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF A LYSA GROUP TRIAL  
R. Gressin, Grenoble (France)

09:15  133  IBRUTINIB-RITUXIMAB FOLLOWED BY REDUCED CHEMO-IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: A WINDOW OF OPPORTUNITY TO REDUCE CHEMO  
M.L. Wang, Houston, TX (USA)

09:30  134  IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY  
S. Rule, Plymouth (UK)

09:45  135  COMBINATION IBRUTINIB (IBR) AND VENETOCLAX (VEN) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL): PRIMARY ENDPOINT ASSESSMENT OF THE PHASE 2 AIM STUDY  
C.S. Tam, Melbourne (Australia)

10:00 – 10:15  BREAK

10:15 – 11:15  SESSION 12 – MARGINAL ZONE LYMPHOMA
Co-chairs: A. Lopez-Guillermo, Barcelona (Spain) and S. Montoto, London (UK)

10:15  136  INTERFERON-FREE ANTIVIRAL TREATMENT IN B-CELL LYMPHOPROLIFERATIVE DISORDERS ASSOCIATED WITH CHRONIC HEPATITIS-C VIRUS INFECTION  
M. Frigeni, Pavia (Italy)
10:30  137  IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN A SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL)
M. Herold, Erfurt (Germany)

10:45  138  LONG-TERM RESULTS OF THE MULTICENTER PHASE II TRIAL WITH BENDAMUSTINE AND RITUXIMAB AS FIRST LINE TREATMENT FOR PATIENTS WITH MALT LYMPHOMA (MALT-2008-01)
A. Salar, Barcelona (Spain)

11:00  139  PHASE IIIB STUDY OF LENALIDOMIDE PLUS RITUXIMAB FOLLOWED BY MAINTENANCE IN RELAPSED OR REFRACTORY NHL: ANALYSIS OF MARGINAL ZONE LYMPHOMA
M. Coleman, New York, NY (USA)

11:15 – 11:40  14-ICML HIGHLIGHTS  📺
Room A and B
“TAKE HOME MESSAGES”
J.W. Friedberg, Rochester, NY (USA)

11:40 – 11:50  CLOSURE AND FAREWELL
F. Cavalli, Bellinzona (Switzerland)

13:30 – 18:15  WORKSHOP - NEW DEVELOPMENTS IN CANINE LYMPHOMA
Room B
Co-chairs: S. Comazzi, Milan (Italy), F. Guscetti, Zurich (Switzerland) and L. Marconato, Bologna (Italy)
Organized by the European Canine Lymphoma Network
open to all 14-ICML attendees

- Updated on June 05, 2017 -